VirginiaMKlimekMD

Oncology • New York, NY

Assistant Professor, Medicine, Weill Cornell Medical College

Join to view full profile

Dr. Klimek is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Klimek's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10065
Phone+1 212-639-2000

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1997
Rutgers Robert Wood Johnson Medical SchoolClass of 1994

Certifications & Licensure

NC State Medical License 2020 - 2022
NY State Medical License 1995 - 2022
NJ State Medical License 2015 - 2021

Clinical Trials

Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia Start of enrollment: 1999 Aug 01
Completed
Phase 1
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma Start of enrollment: 2002 May 01
Completed
Phase 2
An Open-Label, Phase II (Proof Of Concept) Trial Of PKC412 Monotherapy In Patients With Acute Myeloid Leukemia (AML) And Patients With High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2002 Mar 01
A Multicenter, Single-Arm, Open-Label Study Of The Efficacy And Safety Of CC-5013 Monotherapy In RBC Transfusion-Dependent Subjects With Myelodysplastic Syndromes Start of enrollment: 2003 Sep 01
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2006 Jul 01
Completed
Phase 1, Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Mar 01
Withdrawn
Phase 1, Phase 2
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio Start of enrollment: 2011 May 01
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes Start of enrollment: 2014 Aug 27
Completed
Phase 2
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors Start of enrollment: 2017 Aug 07
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

350 citations
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.
Michael Seiler, Akihide Yoshimi, Rachel Darman, Betty Chan, Keaney Gregg F
Nature Medicine. 2018-02-19
476 citations
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
Richard Stone, Daniel J. DeAngelo, Virginia M. Klimek, Ilene Galinsky, Eli Estey
Blood. 2005-01-01
358 citations
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Sean M. Devlin, Heinz Tuechler
Nature Medicine. 2020-08-03

Journal Articles

End-of-Life Care for Older AML Patients Relapsing After Allogeneic Stem Cell Transplant at a Dedicated Cancer Center
Sergio A Giralt, Virginia M Klimek, Richard J Lin, Ann A Jakubowski, Esperanza B Papadopoulos, Parastoo B Dahi, Nature

Abstracts/Posters

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Interplay Between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal HematopoiesisJanuary 12th, 2021